{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:25:47Z","timestamp":1787250347699,"version":"build-2736575974"},"reference-count":103,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple sclerosis (MS) is the most prevalent immune\u2010mediated neurodegenerative disease affecting the central nervous system. Ocrelizumab, a humanized anti\u2010CD20 monoclonal antibody, has demonstrated significant efficacy in reducing disease activity and improving clinical outcomes of people with MS (PwMS) in clinical trials. However, real\u2010world data are crucial for assessing the efficacy and safety of ocrelizumab. Thus, the current study aimed to evaluate the long\u2010term clinical and psychological efficacy and safety profile of ocrelizumab in PwMS compared with other disease\u2010modifying therapies (DMTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This longitudinal study was carried out between January 2022 and February 2024 in Isfahan, Iran. 51 PwMS were included, of whom 21 patients were DMT\u2010na\u00efve, while 30 patients were on other DMTs, including interferon\u2010\u03b2, fingolimod, dimethyl fumarate, natalizumab, or teriflunomide. Demographic characteristics, clinical outcomes, including Expanded Disability Status Scale (EDSS), annualized relapse rate (ARR), timed 25\u2010foot walk (T25FW) test, and nine\u2010hole peg test (9\u2010HPT), as well as psychological measures including anxiety, depression, and fatigue, were evaluated at baseline (T0), and 12 months (T1) and 24 months (T2) of follow\u2010up. Adverse events (AEs) were obtained using chart review and patient self\u2010reports in clinical visits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ARR was significantly decreased at T1 (Z\u2009=\u2009\u22125.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and T2 (Z\u2009=\u2009\u22124.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in PwMS who received ocrelizumab. Similarly, a significant decrease was found in 9\u2010HPT (Z\u2009=\u2009\u22125.16,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and T25FW (Cohen's d\u2009=\u2009\u22120.72,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at T1. Depression and fatigue significantly improved at T1 (Z\u2009=\u2009\u22123.89,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, Cohen's d\u2009=\u2009\u22121.16,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively) and further at T2 (Z\u2009=\u2009\u22122.18,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029, Cohen's d\u2009=\u2009\u22121.59,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively), and anxiety at T1 (Z\u2009=\u2009\u22123,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). PwMS who initiated ocrelizumab as a first\u2010line therapy showed a significantly greater reduction in ARR, 9\u2010HPT, and T25FW than those previously treated with other DMTs (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), while no significant differences were observed in terms of changing EDSS, anxiety, depression, or fatigue levels. Respiratory infections (13.7%), infusion\u2010related reactions (5.9%), and headache (5.9%) were the most frequent AEs, and no serious infection was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ocrelizumab may reduce disease activity and improve functional and psychological outcomes in PwMS, while maintaining a favorable safety profile. Moreover, relapse rates and functional impairment were improved more in groups that initiated ocrelizumab as a first\u2010line therapy than in other disease\u2010modifying therapies. These findings suggest that ocrelizumab is a promising first\u2010line treatment in MS. However, further studies are needed to confirm these preliminary results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.72142","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T05:41:08Z","timestamp":1774244468000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long\u2010Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real\u2010World Longitudinal Study"],"prefix":"10.1002","volume":"9","author":[{"given":"Majid","family":"Jafari","sequence":"first","affiliation":[{"name":"Clinical Research Development Unit, Kashani Hospital Shahrekord University of Medical Sciences Shahrekord Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-9544","authenticated-orcid":false,"given":"Mohammad","family":"Yazdan Panah","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-7419","authenticated-orcid":false,"given":"Saeed","family":"Vaheb","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-9404","authenticated-orcid":false,"given":"Iman","family":"Adibi","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Department of Neurology Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4881-958X","authenticated-orcid":false,"given":"Fereshteh","family":"Ashtari","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Department of Neurology Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-4153","authenticated-orcid":false,"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Department of Neurology Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Zabeti","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Cincinnati Cincinnati OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-2985","authenticated-orcid":false,"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Department of Neurology Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0041-4"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054375"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.049"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12007-3"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10100758"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243543"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600089"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51732"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211005657"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.592304"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118129"},{"issue":"2","key":"e_1_2_15_13_1","first-page":"210","article-title":"Real World Experience With Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis: Insights From the German Neuro Trans Data Registry","volume":"27","author":"Braune S.","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1457788"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00728-8"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844461"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05165-7"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-024-09640-8"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103706"},{"key":"e_1_2_15_20_1","first-page":"662","article-title":"A 1 Year Follow\u2010Up Study of an Italian Cohort of Primary Progressive Multiple Sclerosis (PPMS) Patients Treated With Ocrelizumab: Changes of Clinical, Radiological, Psychological and Biological Markers","volume":"26","author":"Impellizzeri M.","year":"2019","journal-title":"European Journal of Neurology"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2020-000108"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12060127"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02011-w"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020553"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1380654"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13133-w"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104400"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000719"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2021.1989193"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51282"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11969-8"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051326"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000367614"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-601"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5394.1999.07205.x"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008519"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517690823"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410130302"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.875456"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06838-1"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.10.2.83"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20070"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.56.6.893"},{"key":"e_1_2_15_48_1","volume-title":"Psychometric Properties of the Persian Version of Beck Anxiety Inventory (BAI)","author":"Kaviani H.","year":"2008"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520460115022"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(91)90027-M"},{"issue":"9","key":"e_1_2_15_51_1","first-page":"974","article-title":"Fatigue Severity Scale: The Psychometric Properties of the Persian\u2010Version in Patients With Multiple Sclerosis","volume":"4","author":"Azimian M.","year":"2009","journal-title":"Research Journal of Biological Sciences"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008879"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285612474333"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008930"},{"key":"e_1_2_15_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12220"},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110266"},{"key":"e_1_2_15_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01104-8"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105594"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10950-7"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"e_1_2_15_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75745-y"},{"key":"e_1_2_15_63_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010376"},{"key":"e_1_2_15_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15142"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211035740"},{"key":"e_1_2_15_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13283-x"},{"key":"e_1_2_15_67_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210049"},{"key":"e_1_2_15_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1568"},{"key":"e_1_2_15_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40940-w"},{"key":"e_1_2_15_70_1","doi-asserted-by":"publisher","DOI":"10.1177\/2055217320911939"},{"key":"e_1_2_15_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30342-2"},{"key":"e_1_2_15_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103171"},{"key":"e_1_2_15_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102186"},{"key":"e_1_2_15_74_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000237641.33768.8d"},{"key":"e_1_2_15_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61259-9"},{"key":"e_1_2_15_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-021-00677-1"},{"key":"e_1_2_15_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00965-7"},{"key":"e_1_2_15_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11193-w"},{"key":"e_1_2_15_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520946017"},{"key":"e_1_2_15_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01037-2"},{"key":"e_1_2_15_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00320-w"},{"key":"e_1_2_15_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106600"},{"key":"e_1_2_15_83_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008189"},{"key":"e_1_2_15_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09248-6"},{"key":"e_1_2_15_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23732"},{"key":"e_1_2_15_86_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1070238"},{"key":"e_1_2_15_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867"},{"key":"e_1_2_15_88_1","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211007523"},{"key":"e_1_2_15_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0444-x"},{"key":"e_1_2_15_90_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100048691"},{"key":"e_1_2_15_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.07.010"},{"key":"e_1_2_15_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52167"},{"key":"e_1_2_15_93_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200185"},{"key":"e_1_2_15_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.07.003"},{"key":"e_1_2_15_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577721"},{"key":"e_1_2_15_96_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241261565"},{"key":"e_1_2_15_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8594-9"},{"key":"e_1_2_15_98_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365"},{"key":"e_1_2_15_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116973"},{"key":"e_1_2_15_100_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241309835"},{"key":"e_1_2_15_101_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0522"},{"key":"e_1_2_15_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09391-0"},{"key":"e_1_2_15_103_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1295770"},{"key":"e_1_2_15_104_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2574668"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.72142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.72142","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.72142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:50:58Z","timestamp":1787248258000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.72142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/hsr2.72142"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.72142","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72142"}}